or Try an Advanced Search...

    Biopharmaceutical Development Stocks List

    Symbol Grade Name % Change
    MRVI B Maravai LifeSciences Holdings, Inc. -1.00
    IQV D IQVIA Holdings, Inc. -0.55
    BLRX F BioLineRx Ltd. -3.34
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Biotechnology Life Sciences Acid Acute Myeloid Leukemia Antibody Assay Development Services Autoimmune Disease Biology Biopharmaceutical Biopharmaceutical Products Central Nervous System Disease Chemical Synthesis Clinical Development Clinical Research Clinical Trial Compugen Drug Discovery Drug Therapies Gene Therapy Genscript Biotech

    Related ETFs - A few ETFs which own one or more of the above listed Biopharmaceutical Development stocks.

    Symbol Grade Name Weight
    EKG C First Trust Nasdaq Lux Digital Health Solutions ETF 7.17
    BBH C Market Vectors Biotech ETF 4.49
    IBB D iShares Nasdaq Biotechnology Index Fund 4.21
    MID A American Century Mid Cap Growth Impact ETF 3.8
    VNMC D Natixis Vaughan Nelson Mid Cap ETF 2.76
    View all Biopharmaceutical Development ETFs...
    Compare ETFs
    Compare BBH to MID Compare EKG to IBB Compare EKG to VNMC

        Biopharmaceutical Development Stocks Recent News

        Date Stock Title
        May 9 MRVI Maravai LifeSciences Holdings, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 9 MRVI Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript
        May 8 MRVI Maravai LifeSciences Holdings GAAP EPS of -$0.09 misses by $0.04, revenue of $64.2M beats by $3.65M
        May 8 MRVI Maravai LifeSciences Reports First Quarter 2024 Financial Results
        May 7 MRVI Maravai LifeSciences Holdings Q1 2024 Earnings Preview
        May 6 IQV What's in Store for International Money's (IMXI) Q1 Earnings?
        May 6 IQV Is IQVIA Holdings Inc.'s (NYSE:IQV) ROE Of 21% Impressive?
        May 6 BLRX BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
        May 4 IQV IQVIA Holdings Inc. (NYSE:IQV) Q1 2024 Earnings Call Transcript
        May 3 IQV Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
        May 3 IQV IQVIA Holdings Inc (IQV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...
        May 3 IQV Q1 2024 IQVIA Holdings Inc Earnings Call
        May 2 IQV IQVIA Holdings Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 2 IQV IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1
        May 2 IQV IQVIA Holdings Inc. (IQV) Q1 2024 Earnings Call Transcript
        May 2 IQV IQVIA Holdings Inc (IQV) First Quarter 2024 Earnings: Surpasses Revenue Estimates
        May 2 IQV IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
        May 2 IQV An Intrinsic Calculation For IQVIA Holdings Inc. (NYSE:IQV) Suggests It's 30% Undervalued
        May 2 IQV IQVIA Non-GAAP EPS of $2.54 beats by $0.06, revenue of $3.74B beats by $30M
        May 2 IQV IQVIA Reports First-Quarter 2024 Results
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Biotechnology Life Sciences Acid Acute Myeloid Leukemia Antibody Assay Development Services Autoimmune Disease Biology Biopharmaceutical Biopharmaceutical Products Central Nervous System Disease Chemical Synthesis Clinical Development Clinical Research Clinical Trial Compugen Drug Discovery Drug Therapies Gene Therapy Genscript Biotech
        Biopharmaceutical Development

        Biopharmaceutical development is the process of developing biopharmaceuticals, which are drugs derived from biological sources. This process involves the identification of a target molecule, the development of a drug candidate, and the clinical testing of the drug candidate. The development process also includes the manufacturing of the drug, regulatory approval, and commercialization.

        Browse All Tags